Cyclacel Pharmaceuticals (NASDAQ:CYCC) Downgraded to “Sell” at Zacks Investment Research

Zacks Investment Research cut shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) from a hold rating to a sell rating in a report published on Friday morning, reports.

According to Zacks, “CYCLACEL is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Three orally-available Cyclacel drugs are in clinical development. Sapacitabine, a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and cutaneous T-cell lymphoma. Seliciclib (CYC202 or R-roscovitine), a CDK inhibitor, is in Phase 2 for the treatment of lung cancer and nasopharyngeal cancer. “

CYCC has been the subject of several other research reports. Roth Capital reaffirmed a buy rating on shares of Cyclacel Pharmaceuticals in a report on Thursday, May 23rd. HC Wainwright reaffirmed a buy rating on shares of Cyclacel Pharmaceuticals in a report on Wednesday, May 15th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. The stock presently has a consensus rating of Hold and an average target price of $5.00.

Shares of Cyclacel Pharmaceuticals stock opened at $0.46 on Friday. The business has a fifty day simple moving average of $0.55 and a two-hundred day simple moving average of $0.69. Cyclacel Pharmaceuticals has a 1 year low of $0.28 and a 1 year high of $1.87. The company has a market capitalization of $8.08 million, a price-to-earnings ratio of -0.74 and a beta of 2.98. The company has a debt-to-equity ratio of 0.08, a current ratio of 7.26 and a quick ratio of 8.09.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last announced its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.01). As a group, equities analysts anticipate that Cyclacel Pharmaceuticals will post -0.65 earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Cyclacel Pharmaceuticals stock. Renaissance Technologies LLC grew its position in shares of Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) by 82.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,102,400 shares of the biotechnology company’s stock after buying an additional 498,200 shares during the period. Renaissance Technologies LLC owned approximately 6.41% of Cyclacel Pharmaceuticals worth $596,000 at the end of the most recent quarter. 8.61% of the stock is currently owned by hedge funds and other institutional investors.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include CYC065, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias.

Recommended Story: Operating Income

Get a free copy of the Zacks research report on Cyclacel Pharmaceuticals (CYCC)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with's FREE daily email newsletter.